磷脂酰肌醇蛋白聚糖3(GPC3)多克隆抗体
Polyclonal Antibody to Glypican 3 (GPC3)
DGSX; OCI5; SDYS; SGB; SGBS1; MXR7; Glypican Proteoglycan 3; GTR2-2; Intestinal protein OCI-5; Secreted glypican-3
- 编号PAA971Mu01
- 物种Mus musculus (Mouse,小鼠) 相同的名称,不同的物种。
- 来源多抗制备
- 宿主兔
- 效价-
- Ig类型 IgG
- 纯化方式抗原特异性亲和纯化
- 标记物无标记物
- 免疫原 RPA971Mu01-磷脂酰肌醇蛋白聚糖3(GPC3)重组蛋白
- 缓冲液成份0.01M 磷酸盐缓冲液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性状液体
- 浓度0.5mg/mL
- 且适物种-
- 应用WB; IHC; ICC; IP.
如果抗体需用于流式细胞术,请参见流式抗体。 - 下载 英文说明书 中文说明书
- 规格 20µl100µl 200µl 1ml 10ml
- 价格 ¥ 583 ¥ 1361 ¥ 1944 ¥ 4860 ¥ 19440
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
该抗体是针对GPC3的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别GPC3。
用法
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
赠品
增值服务
相关产品
编号 | 适用物种:Mus musculus (Mouse,小鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPA971Mu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA971Mu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)活性蛋白 | Cell culture; Activity Assays. |
PAA971Mu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)多克隆抗体 | WB; IHC; ICC; IP. |
SEA971Mu | 磷脂酰肌醇蛋白聚糖3(GPC3)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
参考文献
杂志 | 参考文献 |
Nature and Science | Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma [Sciencepub:10043238] |
Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG2 cell line [Ebscohost: Source] |
Asian Pacific Journal of Cancer Prevention | Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients? [Pubmed: 24460300] |
Clin Biochem. | Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis [Pubmed: 24362268] |
Science and Nature | Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma [Zolcat: Source] |
Alexandria Journal of Medicine | Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis [ScienceDirect: S2090506814000062] |
J Egypt Natl Canc Inst. | Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. [Pubmed:24841158] |
European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma [Pubmed:25449037] |
Hepatobiliary Pancreat Dis Int | Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern [abstract:abstract4525.shtml] |
Clinical and Molecular Hepatology | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis [pmc:articles] |
Wiley | Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment [pubmed:28621802] |
Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and [Pubmed:29669302] |
Journal of Cancer and Clinical Oncology | Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma [Researchgate:Source] |
Turkish journal of oncology | Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma [10.5505:tjo.2018.1742] |
Intensive Care Medicine Experimental | Elevated plasma glypicans are associated with organ failure in patients with infection [Pubmed: 30618011] |
VALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) [] | |
ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C [] |
Life Sci | Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and … [Pubmed:35640776] |
留言咨询